M
Mary Frances McMullin
Researcher at Queen's University Belfast
Publications - 348
Citations - 13781
Mary Frances McMullin is an academic researcher from Queen's University Belfast. The author has contributed to research in topics: Myelofibrosis & Medicine. The author has an hindex of 54, co-authored 323 publications receiving 12090 citations. Previous affiliations of Mary Frances McMullin include Belfast City Hospital & Queen's University.
Papers
More filters
Journal ArticleDOI
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Linda M. Scott,Wei Tong,Ross L. Levine,Michael A. Scott,Philip A. Beer,Michael R. Stratton,P. Andrew Futreal,Wendy N. Erber,Mary Frances McMullin,Claire N. Harrison,Alan J. Warren,Alan J. Warren,D. Gary Gilliland,D. Gary Gilliland,Harvey F. Lodish,Anthony R. Green,Anthony R. Green +16 more
TL;DR: Four somatic gain-of-function mutations affecting JAK2 exon 12 define a distinctive myeloproliferative syndrome that affects patients who currently receive a diagnosis of polycythemia vera or idiopathic erythrocytosis.
Journal ArticleDOI
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui,Giovanni Barosi,Gunnar Birgegård,Francisco Cervantes,Guido Finazzi,Martin Griesshammer,Claire N. Harrison,Hans Carl Hasselbalch,Rüdiger Hehlmann,Ronald Hoffman,Jean-Jacques Kiladjian,Kröger N,Ruben A. Mesa,Mary Frances McMullin,Animesh Pardanani,Francesco Passamonti,Alessandro M. Vannucchi,Andreas Reiter,Richard T. Silver,Srdan Verstovsek,Ayalew Tefferi +20 more
TL;DR: A review of critical concepts and recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, first- and second-line therapy, and therapy for special issues are presented.
Journal ArticleDOI
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment†‡
Alan Kenneth Burnett,Donald Milligan,Archie G. Prentice,Anthony H. Goldstone,Mary Frances McMullin,Robert Kerrin Hills,Keith Wheatley +6 more
TL;DR: The survival of older patients with acute myeloid leukemia has not improved and few clinical trials have been available for older patients who are not considered fit for an intensive chemotherapy approach.
Journal ArticleDOI
Classification and Personalized Prognosis in Myeloproliferative Neoplasms.
Jacob Grinfeld,Jyoti Nangalia,E. Joanna Baxter,David C. Wedge,Nicos Angelopoulos,Robert Cantrill,Anna L. Godfrey,Elli Papaemmanuil,Gunes Gundem,Cathy MacLean,Julia Cook,Laura O'Neil,Sarah O’Meara,Jon W. Teague,Adam P. Butler,Charles E. Massie,Nicholas Williams,Francesca L. Nice,Christen Lykkegaard Andersen,Hans Carl Hasselbalch,Paola Guglielmelli,Mary Frances McMullin,Alessandro M. Vannucchi,Claire N. Harrison,Moritz Gerstung,Anthony R. Green,Peter J. Campbell +26 more
TL;DR: Comprehensive genomic characterization identified distinct genetic subgroups and provided a classification of myeloproliferative neoplasms on the basis of causal biologic mechanisms and may support the treatment of patients with myelofibrosis.
Journal ArticleDOI
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Alan Kenneth Burnett,Nigel H. Russell,Robert Kerrin Hills,David T. Bowen,Jonathan Kell,Steven Knapper,Yvonne G Morgan,Jennie Lok,Angela Grech,Gail Jones,Asim Khwaja,Lone Smidstrup Friis,Mary Frances McMullin,Ann Hunter,Richard E. Clark,David Grimwade +15 more
TL;DR: A chemotherapy-free ATRA and arsenic trioxide treatment regimen with the standard chemotherapy-based regimen (ATRA and idarubicin) in both high-risk and low-risk patients with acute promyelocytic leukaemia is compared.